Thrombocytopenia in patients with chronic hepatitis C represents an obstacle for the initiation of antiviral treatment. Antiviral treatment with pegylated interferon α and ribavirin has contributed to a significant increase in the rate of sustained virological response. However, patients with thrombocytopenia is ineligible for antiviral treatment or, if able to start treatment, may require a dose reduction or even discontinuation due to the haematological adverse effects. We here review the efficacy and safety of antiviral treatment after splenectomy and partial splenic embolization, and the potential effect of platelet count increase by interferon β.
|ジャーナル||Nihon rinsho. Japanese journal of clinical medicine|
|出版ステータス||出版済み - 2 1 2015|
All Science Journal Classification (ASJC) codes